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Summary High levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in breast cancer
tissue extracts have been associated with rapid disease progression. In these studies, different enzyme-linked immunosorbent assay (ELISA)
kits have been applied forthe quantification, and consequently the ranges of uPA and PAI-1 levels reported differ considerably. Therefore, the
Receptor and Biomarker Study Group (RBSG) of the European Organization for Research and Treatment of Cancer (EORTC) and a
consortium of the BIOMED-1 project 'Clinical Relevance of Proteases in Tumor Invasion and Metastasis' initiated three collaborative
between-laboratory assessment trials aimed at controlling uPA and PAI-1 antigen analyses. For this purpose, two control preparations were
produced from different sources: pooled human breast cancer specimens (QC-240893) and human breast cancer xenografts raised in nude
mice (QC-101094). The lyophilized preparations were stable for prolonged times (at least 3 and 27 months respectively) at 40C. Furthermore,
a good parallelism following dilution was found for uPA and PAI-1. The data from QC trial no. 1 clearly indicated that acceptable between-
laboratory coefficients of variation (CVs) for uPA (<8.2%) and PAI-1 (<16.6%) in QC-240893 could be achieved when the same type of ELISA
kit (American Diagnostica) was used. From the second trial, in which ten EORTC laboratories each received five identical lyophilized QC-
101094 samples, it appeared that the within-laboratory variations for uPA and PAI-1 determinations obtained by 'experienced' laboratories
were lower (<12.9%) than those from non-experienced laboratories (<36.4%). In a third QC trial, five BIOMED-1 laboratories, all of which
employed ELISA procedures for uPA and PAI-1, participated in six subsequent quality assessment rounds receiving five samples of QC-
101094. Although for each laboratory the within-run CVs for uPA as well as for PAI-1 were low (<7.8%), the between-run CVs were found to
be considerably higher (up to 56.2% for uPA and to 27.6% for PAI-1). Consequently, because of the different ELISA formats used, the
absolute analyte values measured in the different laboratories varied substantially. The use of 'common external standards' in the different
ELISAs resulted in a significant reduction of the between-laboratory CVs from 61.3% to 15.7% (uPA) and from 42.1% to 19.1% (PAI-1). The
present data demonstrate that in multicentre studies the same ELISA kit should be used, and that external quality assurance (QA) is
mandatory. Furthermore, it appears from the present study that standardization of the protein assay as a tissular parameter is imperative.
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During the past decade, convincing evidence has accumulated progression and early death (Duffy et al, 1988; Janicke et al, 1990;
suggesting that the urokinase-type plasminogen activator (uPA) Foekens et al, 1992, 1995, Spyratos et al, 1992; Duffy, 1996).
plays a key role in the process of metastasis of human breast Likewise, high levels of the uPA inhibitor PAI-1 also correlate
cancer and of other solid malignant tumours (Mignatti and Rifkin, with shorter relapse-free and overall survival of the breast cancer
1993; Duffy, 1996; Andreasen et al, 1997; Schmitt et al, 1997). patients (Janicke et al, 1991, 1993; Gr0ndahl-Hansen et al, 1993;
High levels of uPA antigen in cytosolic extracts ofhuman primary Bouchet et al, 1994; Foekens et al, 1994). These conclusions were
breast cancer tissue have been associated with rapid disease drawn from studies which made use of enzyme-linked immuno-
sorbent assays (ELISA) for uPA and PAI-1. However, the ELISA
Received27November 1997 kits employed differed substantially in the type of antibodies and
Revised 11 February 1998 standards used. Furthermore, no consensus was reached on how
Accepted 16 February 1998 the tumour tissue extracts had to be prepared. Notwithstanding
Correspondence to: Th J Benraad, 530 Department of Chemical these differences in analytical features, causing different ranges of
Endocrinology, University Hospital St. Radboud, University of Nijmegen, values and cut-offpoints, the same above-mentioned clinical rele-
PO Box 9101, 6500 HB Nijmegen, The Netherlands vance for uPA and PAI-1 emerged from all of these studies.
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Figure 1 Effect of storage on the stability of uPA (A and B) and PAI-1 (C and D) antigen levels in breast cancer xenograft (QC-101094) reference preparations.
Antigen values were determined using either the Nijmegen in-house (A and C) or American Diagnostica (B and D) ELISAs. Vials containing the lyophilized
tissue extract preparations were stored at 40C. The experiments with the Nijmegen in-house method were performed between February 1995 and May 1997,
and with the American Diagnostica ELISA between November 1994 and July 1995
Nevertheless, the obvious discrepancy between the absolute
analyte levels obtained using different ELISAs makes it impos-
sible simply to pool data obtained in multicentre studies.
Therefore, it has been emphasized that pooling of data is feasible
only if the determinations in the various participating laboratories
are performed with the same ELISA and ifexternal quality control
on the antigen determinations is included (Benraad et al, 1996).
On the basis of these considerations, the Receptor and
Biomarker Study Group (RBSG) ofthe EORTC and a consortium
of the BIOMED-1 project 'Clinical Relevance of Proteases in
Tumor Invasion and Metastasis' initiated three collaborative
between-laboratory trials assessing uPA and PAI- 1 antigen
analyses. Such trials require the distribution of quality control
material similar in composition to that of the tumour cytosolic
extracts. Two different control preparations were prepared from
different sources: a pool of residual human primary breast cancer
specimens (QC-240893) and a pool of human breast cancer
xenograft tissue raised in nude mice (QC-101094). These pools
were checked with regard to homogeneity, storage stability and
parallelism before they were used in the quality control trials. The
results ofthis evaluation and ofthe trials are presented below.
MATERIALS AND METHODS
Organization
Within the framework of both the RBSG of the EORTC and a
consortium of the BIOMED-1 project 'Clinical Relevance of
Proteases in Tumour Invasion and Metastasis' (coordinated by M
Schmitt, Munich, Germany), three quality control (QC) trials were
carried out in a multicentre setting to investigate the performance
of uPA and PAI-1 antigen determinations in cytosolic extracts of
human breast cancer tissue. The Nijmegen laboratory, which orga-
nized these trials, has for several years functioned within the RBSG
as quality assessment centre. In addition, within the EUROpath
project (coordinated by G Brugal, Grenoble, France), this labora-
tory is involved in the development ofguidelines forquality assess-
ment procedures regarding biological tumour markers.
QC trial no. 1 is part ofthe protocol of a German multicentre clin-
ical study on adjuvant chemotherapy in node-negative breast cancer,
based on stratification of patients by elevated levels of the tumour
biological factors uPA and PAI-1. This study is coordinated by F
Janicke, Hamburg, Germany. In this trial, the six participating insti-
tutes all used ELISA kits manufactured by American Diagnostica
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(Greenwich, USA) to determine uPA as well as PAI-I antigen. In
two successive rounds (1996-1 and 1996-2) ofthis ongoing trial, all
participating laboratories employed uPA and PAI-l kits ofthe same
lot. In both rounds, the QC-240893 preparation (see below) was
used, divided into two batches, designated 1996-1-A and 1996-1-B,
and 1996-2-A and 1996-2-B respectively.
QC trial no. 2 was initiated by the RBSG. Ten EORTC laborato-
ries from five European countries participated. Eight ofthem used
kits from American Diagnostica, whereas two of the laboratories
employed in-house ELISA formats. The American Diagnostica
ELISA kits used were from different batches. Some of the labora-
tories (n = 7) could be regarded as 'experienced', whereas some of
the participating laboratories (n = 3) were using the kits for the
first time. Each laboratory received five identical lyophilized
samples ofQC-101094. Neither the nature nor content ofthe vials
was disclosed to the participants. This trial was set up primarily to
gather information about within-laboratory variation.
QC trial no. 3 was initiated by members of the BIOMED-1
consortium. It included five institutes, each of which participated
in six subsequent quality assessment rounds. All laboratories
employed different ELISA formats. In the first round, five iden-
tical samples ofQC-101094 were assessed. In the next five rounds,
one of the five samples was identical to those of the first round.
This approach was chosen in an attempt to obtain information
about within-run and between-run variation of different assay
procedures.
Preparation of quality control samples
Pooled human breast cancercytosols: QC-240893
Residual human breast cancer specimens were obtained from the
Nijmegen University tumour bank (storage at -80°C). The cancer
tissues were pulverized in the frozen state using a microdis-
membrator (Braun), immediately homogenized in EORTC buffer
without monothioglycerol and glycerol (20 mm potassium
hydrogen phosphate/potassium dihydrogen phosphate, 1.5 mM
potassium EDTA, 3 mM sodium azide, pH 7.4), and subsequently
centrifuged (800g, 20 min, 4°C). Supematants were collected and
subjected to ultracentrifugation (1 h, 105 000 g, 4°C). The high-
speed supematant (also termed as 'cytosol') was mixed with the
cytosol of non-endocrine tissue prepared from calf psoas major
muscle tissue (which was found to contain neither uPA nor PAI-1
using ELISA). The sample was then aliquoted in portions of
0.5 ml, lyophilized, sealed under vacuum and stored at 4°C. Prior
to analysis, the lyophilized samples were reconstituted with 0.5 ml
of 10% glycerol in bidistilled water. After determination of the
protein content (Pierce BCA), the samples were diluted with dilu-
tion buffer according to the manufacturer's instruction. From the
QC-240893 preparation, four QC batches were prepared: 1996-1 -
A, 1996-1-B, 1996-2-A and 1996-2-B. These lots were employed
in QC trial no. 1.
Human breast cancerxenografts: QC-101094
Xenograft tissue, recovered from nude mice implanted with breast
cancer cell line MDA-MB-231, was frozen in liquid nitrogen and
pulverized in the frozen state using a microdismembrator (Braun).
The resulting powder was suspended in EORTC analysis buffer
devoid of monothioglycerol and glycerol. After centrifugation
(105 000 g, 1 h, 4°C), 25-pl portions of the supernatant (cytosol)
were aliquoted, lyophilized and the vials sealed under vacuum and
stored at 4°C. Prior to analysis, the lyophilized samples were
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Figure 2 Effect of storage of lyophilized QC-101094 preparations at 4°C,
200C and 370C on the stability of uPA (A) and PAI-1 (B) antigen levels. uPA
and PAI-1 antigen values were determined using the American Diagnostica
ELISA kits
reconstituted in 0.5 ml of the dilution buffer [1% bovine serum
albumin (BSA), 0.1% Triton-X100 in phosphate-buffered saline
(PBS)]. QC-101094 was used in QC trials no. 2 and no. 3.
Analytical methods
The commercially available uPA and PAI-1 ELISAs employed in
the QC trials were from American Diagnostica (Greenwich, CT,
USA) and Oncogene Science (Cambridge, MA, USA). In addition,
two other uPA and PAI-1 ELISA formats were used: the Nijmegen
in-house ELISA and in-house ELISAs based on American
Diagnostica antibodies. The basic characteristics of the different
uPA ELISAs used, including type and range ofstandards supplied,
the type of antibodies employed, and information about the
molecular forms of uPA detected, were addressed earlier at an
EORTC/BIOMED-1 workshop in Nijmegen, and the findings for
six different uPA ELISAs were recently described (Benraad et al,
1996). The ELISAs were used according to the manufacturer's
instructions. The set-up of the Nijmegen in-house assays for uPA
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and PAI-I are described elsewhere (Grebenschikov et al, 1997).
Details ofthe in-house uPA and PAI-1 ELISAs based on American
Diagnostica antibodies are reported elsewhere (Foekens et al,
1992, 1994). Protein was measured using the Pierce-BCA assay.
Standards and reference materials
The standards used in the uPA and PAl-I ELISAs were those
provided by American Diagnostica and Oncogene Science respec-
tively. In addition, in QC trial no. 3, 'common' uPA and PAI-l stan-
dard preparations were provided by the Nijmegen Quality Assurance
Centre and sent to the participants to be included in the different
ELISAs. These standards, designated 'calibration standards' by the
RBSG, are those which are included in the Nijmegen in-house
ELISAs. For uPA ELISA, Saruplase, a recombinant non-glycosyl-
ated pro-urokinase preparation produced by Escherichia coli, kindly
provided by Grunenthal, Stolberg, Germany, was used (Benraad et
al, 1996). For PAI-I ELISA, a PAI-I preparation isolated from the
culture medium of the HT1080 cell line, kindly provided by P
Andreasen, University ofAarhus, Denmark, was used.
RESULTS
One of the tasks of the RBSG of the EORTC and the BIOMED-1
project 'Clinical Relevance of Proteases in Tumour Invasion and
American Diagnostica
uPA
B A
Metastasis' was to establish, test, harmonize and control uPA and
PAI-1 ELISA assays intended to be used in the determination of
these antigens in human tissue specimens.
Performance of the two quality control preparations,
QC-240893 and QC-101094
Stability ofQC-240893
The stability of QC-240893, which is still used in QC trial no. 1,
was verified by analysing this preparation on 23 (uPA) and 19
(PAI-1) separate days over a period of 3 months, during which the
lyophilized QC vials were stored at 4°C. The analyses were
performed by one laboratory employing the American Diagnostica
uPA and PAI-1 ELISA kits. The average analyte concentrations
measured were 2.1 ng ml-' for uPA and 19.2 ng ml-' for PAI-l,
with between-run CVs of 9.8% and 5.8% respectively. No statisti-
cally significant trends were observed.
Parallelism study on QC-240893
Parallelism was investigated employing American Diagnostica
uPA and PAI-I kits and QC-240893. For this purpose, dilutions of
1:4, 1:8, 1:16, 1:32 and 1:64 were tested. The uPA values (ng ml-')
corrected for the dilution factor were 1.90, 1.70, 1.80, 1.80 and
2.40 (mean 1.92 ng ml-'; CV 14.4%). The corrected PAI-I values
(ng ml-') were 23.3, 22.6, 18.3, 21.8 and 19.9 (mean 21.1 ng ml-';
CV 9.7%).
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Figure 3 Typical standard curves for uPA (A and B) and PAI-1 (C and D) obtained with the American Diagnostica (A and C) and the Nijmegen in-house (B and
D) ELISAs. The range of OD values obtained in different dilution of the QC-101094 reference preparation is indicated by vertical bars. For uPA, the lyophilized
QC-101094 was reconstituted in 0.4 ml and this solution (designated dilution 1:1) was diluted in five steps with a final dilution 1:15. For PAI-1, the sample was
reconstituted in 0.20 ml and this solution (dilution 1:1) was diluted in five steps with a final dilution 1:25
British Journal ofCancer (1998) 78(11), 1434-1441
1.6
E
c
0
LO
't
co
0 0
CZ
.0
-0
1.2
0.8
0.4
0.0 I
0.00
C
1.5 1
E
Ct
co
0
(0
a
.a2 .0
.0
1.0
0.5
0.0 _
0.0
0 CancerResearch Campaign 19981438 CGJ Sweep etal
Table 1 uPA antigen values in QC-240893, assessed by six laboratories involved in a multicentre trial. All labs used ELISA kits from American Diagnostica
Lab. no. 1996-1-A 1996-1-B 1996-2-A 1996-2-B
uPA Protein uPA uPA Protein uPA uPA Protein uPA uPA Protein uPA
(ng ml-') (ng ml-') (ng mg-1 (ng ml-') (ng ml-1) (ng mg-' (ng ml-') (ng ml-') (ng mg-' (ng ml-') (ng ml-') (ng mg-'
protein) protein) protein) protein)
1 2.88 4.72 0.61 3.84 4.74 0.81 4.08 4.03 1.01 3.88 3.39 1.14 2 2.73 4.48 0.61 3.22 4.47 0.72 4.27 5.18 0.82 3.70 5.7 0.65
3 2.75 3.44 0.80 3.50 3.43 1.02 4.15 3.64 1.14 3.70 3.14 1.18
4 2.41 3.43 0.70 3.50 3.06 1.10 3.70 3.36 1.10 3.70 3.08 1.20
5 2.77 3.48 0.80 3.75 3.46 1.08 3.40 3.43 0.99 3.94 3.28 1.20
6 2.58 4.23 0.61 3.30 4.31 0.77 3.96 3.82 1.04 4.38 3.5 1.25 Mean 2.69 3.96 0.69 3.52 3.91 0.92 3.93 3.91 1.02 3.88 3.68 1.10
s.d. 0.17 0.58 0.09 0.24 0.68 0.17 0.32 0.67 0.11 0.26 1.00 0.23
CV (%) 6.2 14.7 13.5 6.9 17.4 18.4 8.2 17.1 10.8 6.8 27.2 20.4
Table 2 PAI-1 antigen values in QC-240893, assessed by six laboratories involved in a multicentre trial. All laboratories used ELISA kits from American
Diagnostica
Lab. no. 1996-1-A 1996-1-B 1996-2-A 1996-2-B
PAI-1 Protein PAI-1 PAI-1 Protein PAI-1 PAI-i Protein PAI-1 PAI-1 Protein PAI-1
(ng ml-') (ng ml-') (ng mg-' (ng ml-') (ng ml-') (ng mg-' (ng ml-') (ng ml-') (ng mg-' (ng ml-') (ng ml-')(ng mg-'
protein) protein) protein) protein)
1 21.49 4.72 4.55 32.44 4.74 6.84 25.48 4.03 6.32 21.57 3.39 6.36
2 15.38 4.48 3.43 22.70 4.47 5.08 25.47 5.18 4.92 24.56 5.7 4.31 3 18.50 3.44 5.38 26.50 3.43 7.73 34.10 3.64 9.37 28.60 3.14 9.11
4 15.90 3.43 4.90 20.20 3.06 6.90 22.20 3.36 6.61 20.60 3.08 6.69 5 21.18 3.48 6.09 28.73 3.46 7.73 24.44 3.43 7.13 25.57 3.28 7.80
6 20.03 4.23 4.74 25.58 4.31 5.95 27.19 3.82 7.12 28.11 3.5 8.03 Mean 18.75 3.96 4.85 26.03 3.91 6.71 26.48 3.91 6.91 24.84 3.68 7.05
s.d. 2.63 0.58 0.89 4.33 0.68 1.04 4.08 0.67 1.45 3.29 1.00 1.67 CV(%) 14.0 14.7 18.3 16.6 17.4 15.5 15.4 17.1 21.0 13.2 27.2 23.6
Homogeneity ofQC-101094
To test the homogeneity oflyophilized QC-101094, ten vials were
randomly selected and uPA and PAI-I antigen levels were
measured in quadruplicate in one assay run using the Nijmegen in-
house and the American Diagnostica ELISAs (both using different
standards). The mean values of uPA obtained with the Nijmegen
in-house method (0.85 ng ml-') were about two times higher than
those obtained with the American Diagnostica kit (0.36 ng ml-').
The average values obtained for PAI-1 with the Nijmegen method
(0.86 ng ml-') were approximately four times lower than those
obtained with the American Diagnostica kit (3.35 ng ml-'). The
between-vial CVs of all assays were less than 4.2%, with no
significant between-vial variation.
Stability ofQC-101094
The stability ofQC-101094 was verified by analysing this prepara-
tion in duplicate on 54 (uPA) and 66 (PAI-1) separate days within
a time frame of 27 months using the Nijmegen in-house ELISAs,
and on 23 separate days during 8 months using the American
Diagnostica ELISA kits. The Nijmegen in-house ELISA measured
average analyte concentrations of 0.87 ng ml-' for uPA and
0.81 ng ml-' for PAI-1, with overall between-run CVs of8.8% and
8.9% respectively. No statistically significant trends were
observed (Figure lA and C). The average analyte concentrations
measured with the American Diagnostica ELISAs were 0.36 ng
ml' for uPA and 3.31 ng ml' for PAI-1, with overall between-run
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CVs of5.0% and 5.4% respectively. Again, no trend was observed
(Figure lB and D).
Lyophilized QC-101094 was stored at 4°C. Temperature
stability was tested after 1, 3, 5, 7 and 9 days of storage at 4°C,
20°C and 37°C. The samples were analysed for uPA and PAI-1
employing the American Diagnostica ELISAs. The antigen values
for uPA and PAI-1, after 9 days of storage at 4°C, were not signif-
icantly different from those of storage at day 1 (Figure 2).
Likewise, after 9 days of storage at 37°C, the uPA and PAI-I
values did not significantly differ from those after 1 day's storage
at this temperature. No significant difference was found for uPA
and PAI-I values when stored at 4°C, 20°C, or 37°C. These find-
ings indicate that both analytes in QC-101094 are not subject to
degradation by exposure ofthe lyophilized preparation to ambient
temperature for at least 9 days.
Parallelism study on QC-101094
In the parallelism study performed on QC-101094, the volume of
the reconstitution bufferemployed and the dilution ofthe reconsti-
tuted preparation were chosen so that the optical density (OD)
values obtained spanned the OD values ofthe uPA and PAI-I stan-
dard curves almost completely. Figure 3 shows typical standard
curves for uPA and PAI-I obtained with the American Diagnostica
and the Nijmegen in-house ELISAs, including the range of
OD450 nm values observed analysing diluted QC-101094 (vertical
bars). Multiplying the analyte concentrations measured in the
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Table 3 uPA and PAI-1 antigen values assessed by ten EORTC
laboratories analysing the QC-101094 preparation in fivefold in one assay
run
Lab. no. uPA (ng ml-1) PAI-i (ng ml-')
Mean s.d. CV(%) Mean s.d. CV(%)
Experienced laboratories using AD ELISA kits
1 0.64 0.05 7.8 3.05 0.09 3.0
2 0.72 0.02 2.9 3.69 0.14 3.8
3 0.57 0.02 3.4 2.24 0.02 0.9
4 0.63 0.05 7.4 2.66 0.14 5.2
5 0.66 0.05 7.7 3.45 0.45 12.9
Non-experienced laboratories usingAD ELISA kits
6 0.55 0.09 16.1 3.33 0.59 17.8
7 0.57 0.15 25.6 2.45 0.39 15.9
8 0.96 0.14 14.3 3.26 1.19 36.4
Experienced laboratories using in-house ELISAs
9 1.53 0.06 4.1 3.44 0.15 4.3
10 1.08 0.03 3.1 0.83 0.04 4.9
AD, American Diagnostica.
diluted samples by the appropriate dilution factor results in the
actual values for the undiluted samples. For uPA, the means of
these values determined with the American Diagnostica ELISA
and the Nijmegen in-house ELISAs were 0.87 ng ml' and 1.18 ng
ml-', with CVs of4.6% and 7.3% respectively. The corresponding
values for PAI-1 were 6.55 ng ml' (CV 8.4%) measured with the
American Diagnostica kit and 1.92 ng ml-' (CV 7.1%) assessed by
the Nijmegen ELISA. For both analytes and both ELISAs, no
systematic decrease or increase in values was seen upon dilution.
Evaluation of the three QC trials
QC trial no. 1
In the first round of this QC trial no. 1, two vials (1996-1-A and
1996-1-B) of QC-240893 were shipped to six laboratories
involved in a German multicentre clinical trial. All laboratories
employed American Diagnostica uPA and PAI-1 ELISA kits. The
average uPA concentration of vial A was 2.69 ng ml' with a
between-laboratory CV of6.2% (Table 1). A similar low between-
laboratory variation was observed analysing vial 1996-1-B. The
variation of the protein concentration in vial A gave a CV of
14.7%. Expressing the analyte concentrations as ng mg-' protein
leads, therefore, to a substantial increase in the between-laboratory
uPA variation, i.e. 13.5%. For vial B, the expression of results in
ng mg-' protein leads to an increase in the between-laboratory
variation from 6.9% to 18.4%. In the second round of this trial,
comparable observations were made (see Table 1). It should be
recalled that in these assay runs the same batch ofELISA kits was
employed.
Table 2 shows corresponding dataregarding the results obtained
in PAI-I analyses. Clearly, the between-laboratory variations seen
here are higher than those observed in the analysis of uPA. If
expressed as ng PAI-I ml', the highest between-laboratory CV is
16.6%. If expressed as ng PAI-I mg-' protein, the highest CV
amounts to 23.6%. One might note that the samples of the first
round, 1996-1-B, are equal to the samples 1996-2-A from the
second round. The analyte levels as well as the protein levels of
these sets of samples appear to match closely.
QC trial no. 2
In this trial, ten EORTC laboratories participated. Seven of them
may be regarded as 'experienced', because in these laboratories
these types of ELISAs have already been used for a number of
years. In one shipment, the participants received five identical
vials of QC-101094, and these were analysed in one assay run. As
can be seen in Table 3, the within-laboratory variation obtained
by the 'experienced' laboratories is lower (range: 0.9-12.9%)
than those from the 'non-experienced' laboratories (range
14.3-36.4%). The between-laboratory CV of the five experienced
laboratories using ELISAs from American Diagnostica was 8.5%
for uPA and 19.4% for PAI-1. As expected, the uPA and PAI-1
values obtained using different ELISAs varied widely, for uPA
from 0.55 ng ml' to 1.53 ng ml' and for PAI-I from 0.83 ng ml'
to 3.69 ng ml'.
QC trial no. 3
This trial encompassed five 'experienced' laboratories, all ofthem
participating in the BIOMED-1 project. Over six consecutive
months, each centre received QC-101094 vials. Each laboratory
used different ELISA formats (Tables 4 and 5). For each labora-
tory the within-run CV was low, ranging from 3.1% to 5.9% for
uPA and from 3.3% to 7.8% for PAI-1. The between-run CVs were
found to be considerably higher, ranging from 8.4% to 56.2% for
Table 4 uPA values (ng ml-1) assessed by five BIOMED-1 laboratories analysing the QC-101094 in fivefold in one assay run (Oct) and in five runs in
subsequent months (Nov-Mar)
Laboratory Oct Nov Dec Jan Feb Mar Nov-Mar
Mean Within-run Mean Between-run
CV (%) CV (%)
A 1.53 3.9 0.37 1.1 1.19 1.7 0.49 0.97 56.2
B 0.61 4.4 0.53 0.56 0.64 0.77 0.64 0.63 14.8
C 0.28 5.9 0.38 0.44 0.51 0.29 0.29 0.38 25.2
D 1.08 3.1 0.97 0.86 0.87 0.77 0.84 0.86 8.4
April 7 April 10 April 11 April 12 April 13 April 14 April 10-14
E 1.42 3.6 1.3 1.48 1.46 1.2 1.56 1.4 10.4
Mean 0.98 0.85
CV 54.3% 45.1%
Mean CV 4.2 23.0
British Journal ofCancer (1998) 78(11), 1434-1441 0 Cancer Research Campaign 19981440 CGJ Sweep etal
Table 5 PAI-1 antigen values (ng ml-1) assessed by five BIOMED-1 laboratories analyzing QC-101094 in fivefold in one assay run (Oct) and in five runs in
subsequent months (Nov-Mar)
Laboratory Oct Nov Dec Jan Feb Mar Nov-Mar
Mean Within-run Mean Between-run
CV(%) CV(%)
A 3.44 4.3 3.51 3.87 3.89 3.72 2.96 3.59 9.6
B 2.84 6.3 3.52 3.2 2.46 2.18 2.03 2.68 21.7
C 0.72 7.8 1.7 1.7 2.25 1.6 0.85 1.62 27.6
D 0.83 4.9 0.92 0.93 0.92 0.84 0.91 0.91 3.6
April 7 April 10 April 11 April 12 April 13 April 14 April 10-14
E 0.84 3.3 0.82 0.84 0.49 0.99 0.87 0.80 20.9
Mean 1.73 1.92
CV 75.0% 62.3%
Mean CV 5.3 16.7
Table 6 Effect of the use of a common uPA and PAI-1 standard instead of
different standards on assay variation
uPA PAI-1
ng ml-' ng ml-1
Laboratory Different* Common** Different* Common**
no. standards standard standards standard
A 0.87 0.87 0.92 0.92
B 1.19 0.75 3.50 0.75
C 0.64 0.67 2.03 1.12
D 0.51 1.10 1.60 0.80
E 1.46 0.90 0.82 0.93
Mean 0.93 0.86 1.77 0.90
CV(%) 41.9 19.1 61.2 15.8
*Analyte values read from dose-response curves, each laboratory using its
own or kit-standard. **Analyte values read from dose-response curves, each
laboratory using a common standard. For uPA: pro-uPA (Saruplase); for PAl-
1: PAI-1 from HT1080 cells.
uPA and from 3.6% to 27.6% for PAI-l. The absolute analyte
values measured in the different laboratories varied widely, for
uPA ranging between 0.37 ng ml-' and 1.56 ng ml and for PAI-I
ranging between 0.49 ng ml-' and 3.89 ng ml', because different
ELISAs were employed.
In the third trial, in addition to QC-101094, external standards
were shipped to the participants. Table 6 shows that, using the
Grunenthal standard Saruplase (a recombinant, non-glycosylated
pro-urokinase form of uPA) as a common uPA standard, the mean
between-laboratory CVs of uPA antigen values measured in the
QC-101094 preparation, using the different ELISAs, dropped from
41.9% to 19.1%. Using the PAI-1 standard prepared by P
Andreasen (PA1-I isolated from culture medium ofthe HT1080 cell
line) as a common external standard in the different PAI-1 ELISAs
resulted in a substantial reduction in CV from 61.2% to 15.8%.
DISCUSSION
From the validation experiments reported here, it appears that both
QC-240893 and QC-101094 preparations can serve as quality
control pools. This is because: (i) both are suitable for shipment at
ambient temperature and are stable for prolonged periods, (ii) both
show parallelism of dose-response curves following dilution, (iii)
uPA and PAl- I levels can be brought into the working range ofthe
assays and (iv) the control material is similar to the patient and
research specimens to be analysed. The source ofthe two prepara-
tions is different: QC-240893 is prepared from pooled residual
breast cancer tissue extracts and QC-101094 from human breast
cancer xenograft tissue. Tumour specimens used for QC-240893
were selected to contain relatively large concentrations ofuPA and
PAI-1. Prior to lyophilization, the blended tumour cytosol was
diluted with a cytosol prepared from calf tissue which was found
to be devoid of uPA and PAI-1. The dilution provided a suffi-
ciently large amount of QC material to be used in the QC trial no.
1. In addition, the protein content ofQC-240893 is high enough to
be determined in the Pierce-BCA assay. A drawback to the use of
such a preparation is the difficulty ofassembling sufficiently large
amounts of QC material for multicentre QC trials. Furthermore, it
may limit the number of assay runs in which the same QC sample
should be used, e.g. for batch-to-batch reproducibility studies. A
second independent source of quality control material was estab-
lished by implanting nude mice with human breast cancer cells to
generate xenograft breast cancer tissue, which can be recovered in
large amounts and contains high enough concentrations of uPA
and PAI-1. From this xenograft material QC-101094 was prepared,
which was employed in the QC trials no. 2 and no. 3.
QC trial no. 1 is part of an ongoing multicentre clinical trial,
from which only the results of the first two quality control rounds
are presented in this report. These results came from six partici-
pating laboratories, all of them using the same batch of American
Diagnostica uPA and PAl-1 ELISA kits. Furthermore, the laborato-
ries received meticulous instructions on how to run the assays, and
thus can be regarded as 'experienced'. This should be taken into
consideration when interpreting the low between-laboratory varia-
tions (average CV 7.1%) obtained measuring the uPA concentra-
tion ofQC-240893 preparation. In this context, it is noteworthy that
the between-laboratory variations observed, measuring the PAI-1
concentration, were larger (average CV 14.9%). 'Normalization' of
the PAI-l values of, for example, sample 1996-1-B, using sample
1996-1-A as the calibrator, resulted in a considerable decrease in
the mean between-laboratory CV from 16.6% to 7.4%. Likewise,
'normalization' of sample 1996-2-B, using sample 1996-2-A as
the calibrator, reduced the CV from 13.2% to 9.5%. This implies
that external reference preparations should be used to normalize
assay results. Obviously, the immunoreactive potency of the
lyophilized standards should be carefully checked, e.g. by
including an external quality-checked reference preparation in each
assay run. Another point emerging from trial no. 1 is that a high
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between-laboratory CV was observed with the protein assay,
resulting in large variations in analyte concentrations if values are
expressed as ng mg-' protein. Certainly, the performance of the
protein assay has to be improved.
QC trial no. 2 was set up primarily to collect information about
within-laboratory variation, analysing uPA and PAI-I. The within
laboratory, within-run CVs obtained by 'experienced' laboratories
were considerably lower than the CVs from the 'non-experienced'
laboratories. Similar results were obtained for PAI-1. This second
trial confirmed the earlier observation that the average between-
laboratory variation, obtained by experienced laboratories
employing American Diagnostica kits, was much lower for the
uPA assay (CV 8.5%) as compared with the variation in the PAI-I
determinations (CV 19.4%).
The absolute analyte values, measured in laboratories using
in-house ELISAs, diverge from those using the American
Diagnostica ELISA kits. This is not surprising if one realizes that
different ELISAs employ different antibodies and standards. In
trial no. 3, we were faced with this situation because here the five
participating laboratories all used different ELISA procedures. In
the first round of this trial, the between-laboratory CV amounted
to 54% for uPA and 75% for PAI-1. Certainly, part of these large
variances must be due to the fact that different standards were used
in the ELISAs (Benraad et al, 1996). The between-laboratory vari-
ations declined from 42% to 19% for uPA and from 61% to 16%
for PAl- if a common standard preparation was used in each
assay. It should be stated that the standards were shipped in the
frozen state and were not lyophilized.
Trial no. 3 disclosed another noteworthy phenomenon. This trial
confirmed that the within-run variations achieved by experienced
laboratories, analysing preparation QC-101094, can be remarkably
low (average 4.3% for uPA and 5.5% for PAI-1). In sharp contrast,
however, were the large variations attained in at least three of the
five laboratories with the between-run experiment (average 29%
for uPA and 19% for PAI-1). The between-run data were obtained
over a period of 5 months, during which time each laboratory
analysed the QC-101094 preparation monthly. The discrepancy
between within-run and between-run variations could be ascribed
both to variation in assay performance by the laboratory staff and
to the instability ofthe standard during its preparation. From these
results it is clear that, if one requires to pool data from measure-
ments over a long period of time, inclusion of an external quality
control sample is most desirable.
In conclusion, the results presented in this report indicate
strongly that external quality assurance by use of checked refer-
ence materials is unavoidable ifuPA and PAI-1 antigen determina-
tions are part of multicentre studies. Also, in multicentre studies,
pooling of analytical data is valid only if the participating labora-
tories all use the same ELISA kits. Furthermore, it appears from
the present study that standardization of the protein assay as a
tissular parameter is imperative. As previously reported (Romain
et al, 1995) and later confirmed (Benraad et al, 1996), the extrac-
tion procedure should also be standardized. Evidently, the present
quality-checked QC breast cancer pools should be made widely
available, so that the reproducibility of the uPA and PAI-1 ELISA
kits can be monitored over a long period of time.
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